Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1)

Oral Oncology

Volumn 70, Issue , 2017, Pages 58-64

  Manos M ^a   Giralt, J ^a   Rueda, A ^b   Cabrera, J ^c   Martinez Trufero, J ^d   Marruecos, J ^e   Lopez Pousa, A ^f   Rodrigo, J P ^g   Castelo, B ^h   Martinez Galan J ⁱ   Arias, F ^j   Chaves, M ^k   Herranz, J J ^l   Arrazubi, V ^m   Baste, N ^a   Castro, A ^h   Mesia R ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e ICO Girona   (Spain)

^f Hospital Sant Pau   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^j Instituto de Investigación Sanitaria de Navarra   (Spain)

^k HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^l HOSPITAL JUAN CANALEJO   (Spain)

^m HOSPITAL DE BASURTO   (Spain)

more..

Author keywords

Clinical guidelines; Delphi methodology; Head and neck cancer; Spanish multidisciplinary consensus

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; DELPHI STUDY; HEAD AND NECK CANCER; HUMAN; LARYNGECTOMY; LARYNGOSCOPY; LARYNX CANCER; LASER SURGERY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SPAIN; TRANSORAL LASER SURGERY; VOICE; CONSENSUS; HEAD AND NECK TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CONSENSUS; DELPHI TECHNIQUE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; SPAIN;

EID: 85017445786     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2017.04.004     Document Type: Review

References (71)

1. Kamangar, F., Dores, G.M., Anderson, W.F., Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:14 (2006), 2137–2150.
2. Rischin, D., Ferris, R.L., Le, Q.T., Overview of advances in head and neck cancer. J Clin Oncol 33:29 (2015), 3225–3226.
3. Hayes, D.N., Van Waes, C., Seiwert, T.Y., Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J Clin Oncol 33:29 (2015), 3227–3234.
4. Braakhuis, B.J., Brakenhoff, R.H., Leemans, C.R., Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol, 23(Suppl 10), 2012 x173-7.
5. Leemans, C.R., Braakhuis, B.J., Brakenhoff, R.H., The molecular biology of head and neck cancer. Nat Rev Cancer 11:1 (2011), 9–22.
6. Seiwert, T.Y., Cohen, E.E., State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92:8 (2005), 1341–1348.
7. Bonner, J.A., Harari, P., Ang, K.K., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354:6 (2006), 567–578.
8. Sacco, A.G., Cohen, E., Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33:29 (2015), 3305–3315.
9. Barton, M.B., Jacob, S., Hanna, T.P., Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 112:1 (2014), 140–144.
10. National Comprehensive Cancer Network: NCCN Practice Guidelines in Oncology: Head and Neck Cancers, 2016. < http://www.nccn.org/professionals/physician_gls/f_guidelines.asp>.
11. Mesía, R., Pastor, M., del Barco, E., SEOM. SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013. Clin Transl Oncol 15:12 (2013), 1018–1024.
12. Lang, J., Gao, L., Zhang, C., Society of Head & Neck Tumor Surgery, Society of Radiation Therapy, Chinese Anti-Cancer Association, Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. Future Oncol 10:9 (2014), 1635–1648.
13. Kuno, H., Onaya, H., Fujii, S., Primary staging of laryngeal and hypopharyngeal cancer: CT, MR imaging and dual energy CT. Eur J Radiol 83:1 (2013), e23–e35.
14. Castelijns, J.A., Gerritsen, G.J., Kaiser, M.C., Invasion of laryngeal cartilage by cancer: comparison of CT and MR imaging. Radiology 167:1 (1988), 199–206.
15. Allegra, E., Ferrise, P., Garozzo, A., Early glottic cancer: role of MRI in the preoperative staging. Biomed Res Int, 2014, 890385.
16. Jones, A.S., Fish, B., Fenton, J.E., et al. The treatment of early laryngeal cancers (T1–T2N0): surgery or irradiation?. Head Neck 26 (2004), 127–135.
17. Ossoff, R.H., Sisson, G.A., Shapshay, S.M., Endoscopic management of selected early vocal cord carcinoma. Ann Otol Rhinol Laryngol 94:6 Pt 1 (1985), 560–564.
18. Remacle, M1., Van Haverbeke, C., Werner, J., Proposal for revision of the European Laryngological Society classification of endoscopic cordectomies. Eur Arch Otorhinolaryngol 4:5 (2007), 499–504.
19. Hartl, D.M., Ferlito, A., Brasnu, D.M., Evidence-based review of treatment options for patients with glottic cancer. Head Neck 33:11 (2011), 1638–1648.
20. Higgins, K.M., Shah, M.D., Ogaick, M.J., Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. J Otolaryngol Head Neck Surg 38 (2009), 603–612.
21. Nonoshita, T., Shioyama, Y., Kunitake, N., Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Fukuoka Igaku Zasshi 100 (2009), 26–31.
22. Constantin balica, N., Mazilu, O., Anterior commissure laryngeal neoplasm endoscopic management. Rom J Morphol Embryol 57:Suppl 2 (2016), 715–718.
23. Taylor, S.M., Kerr, P., Rigby, M.H., Treatment of T1b glottic SCC: laser vs. radiation–a Canadian multicenter study. J Otolaryngol Head Neck Surg, 19(42), 2013, 22.
24. Stoeckli, S.J., Schnieper, I., Huguenin, P., Early glottic carcinoma: treatment according patient's preference?. Head Neck 25 (2003), 1051–1056.
25. 2 laser endoscopic resection of early glottic cancer. Acta Otolaryngol 126:3 (2006), 306–310.
26. Salvador-Coloma, C., Cohen, E., Multidisciplinary care of laryngeal cancer. J Oncol Practice/Am Soc Clin Oncol 12:8 (2016), 717–724.
27. Forastiere, A.A., Weber, R.S., Hopkins, J., Organ preservation for advanced larynx cancer: issues and outcomes. J Clin Oncol 33:29 (2015), 3262–3268.
28. Forastiere, A.A., Goepfert, H., Maor, M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003), 2091–2098.
29. Forastiere, A.A., Zhang, Q., Weber, R.S., Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31 (2013), 845–852.
30. Francis, E., Matar, N., Khoueir, N., T4a laryngeal cancer survival: retrospective institutional analysis and systematic review. Laryngoscope 124 (2014), 1618–1623.
31. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324: 1685–90.
32. Chen, A.Y., Fedewa, S., Zhu, J., Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985–2007. Arch Otolaryngol Head Neck Surg 137 (2011), 1017–1024.
33. Lefebvre, J.L., Chevalier, D., Sahmoud, T., Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:13 (1996), 890–899.
34. Lefebvre, J.L., Andry, G., EORTC Head and Neck Cancer Group, Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 23:10 (2012), 2708–2714 Oct.
35. Pignon, J.P., Bourhis, J., Domenge, C., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 (2011), 949–955.
36. Pignon, J.P., le Mâıtre, A., Maillard, E., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92 (2009), 4–14.
37. Pignon, J.P., Syz, N., Posner, M., Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. AnticancerDrugs 15 (2004), 331–340.
38. Paccagnella, A., Ghi, M.G., Loreggian, L., Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21 (2010), 1515–1522.
39. Vermorken, J.B., Remenar, E., van Herpen, C., Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007), 1695–1704.
40. Janoray, G., Pointreau, Y., Garaud, P., Long-term results of GORTEC 2000-01: a multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation 2015. J Clin Oncol, 33, 2015.
41. Zhang L, Jiang N, Zhao Y. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. Sci Reports; 2015: 10798.
42. Zhang, Y., Guan, J., Chen, L., A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus current radiotherapy for advanced head and neck cancer. ASCO Annu Meet Proc, 33(Suppl 15), 2015, 6035.
43. Monnier, Y., Simon, C., Surgery versus radiotherapy for early oropharyngeal tumors: a never-ending debate. Curr Treat Options Oncol 16:9 (2015), 1–13.
44. Fakhry, C., Zhang, Q., Garden AS Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32:30 (2014), 3365–3373.
45. Holsinger, F.C., Ferris, R.L., Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J Clin Oncol 33:29 (2015), 3285–3292.
46. Bernier, J., Domenge, C., Ozsahin, M., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004), 1945–1952.
47. Hoşal, A.S., Unal, O.F., Ayhan, A., Possible prognostic value of histopathologic parameters in patients with carcinoma of the oral tongue. Eur Arch Otorhinolaryngol 255 (1998), 216–219.
48. Ganly, I., Patel, S., Shah, J., Early stage squamous cell cancer of the oral tongue – clinicopathologic features affecting outcome. Cancer 118 (2012), 101–111.
49. Shim, S.J., Cha, J., Koom, W.S., Clinical outcomes for T1–2N0-1 oral tongue cancer patients underwent surgery with and without postoperativeradiotherapy. Radiat Oncol, 5, 2010, 43.
50. Cooper, J.S., Pajak, T.F., Forastiere, A.A., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004), 1937–1944.
51. Bernier, J., Cooper, J.S., Lefèbvre, J., L Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:10 (2005), 843–850.
52. Chinn, S.B., Myers, J.N., Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol 33:29 (2015), 3269–3276.
53. Bedwinek, J.M., Shukovsky, L.J., Fletcher, G.H., Osteonecrosis in patients treated with definitive radiotherapy for squamous-cell carcinomas of oral cavity and nasopharynx and oropharynx. Radiology 119 (1976), 665–667.
54. Pederson, A.W., Salama, J.K., Witt, M.E., Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol-Cancer Clinical Trials 34 (2011), 356–361.
55. Gore, S.M., Crombie, A.K., Batstone, M.D., Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck 37 (2015), 518–523.
56. Stenson, K.M., Kunnavakkam, R., Cohen, E.E., Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope 120 (2010), 93–99.
57. Cohen, E.E., Baru, J., Huo, D., Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck 31 (2009), 1013–1021.
58. Liao, C.T., Chang, J.T., Wang, H.M., Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer 107 (2006), 337–344.
59. Giralt, J.L., Gonzalez, J., del Campo, J.M., Preoperative induction chemotherapy followed by concurrent chemora- diotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer 89 (2000), 939–945.
60. Licitra, L., Grandi, C., Guzzo, M., et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21 (2003), 327–333.
61. Zhong, L.P., Zhang, C.P., Ren, G.X., Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31 (2013), 744–751.
62. Chinn, S.B., Spector, M.E., Bellile, E.L., Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma. JAMA Otolaryngol Head Neck Surg 140 (2014), 134–142.
63. Bhatia, A., Burtness, B., Human papillomavirus-associated oropharyngeal cancer: defining risk groups and clinical trials. J Clin Oncol 33:29 (2015), 3243–3250.
64. Sher, D.J., Schwartz, D.L., Koshy, M., Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: a population-based analysis. Oral Oncol 54 (2016), 58–67.
65. Haddad, R., O'Neill, A., Adkins, D., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:3 (2013), 257–264.
66. Hitt, R., Grau, J.J., Irigoyen, A., A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25:1 (2014), 216–225.
67. Szturz, P., Vermorken, J.B., Treatment of elderly patients with squamous cell carcinoma of the head and neck. Front Oncol 6:199 (2016), 1–14.
68. Strom, T., Trotti, A., Caudell, J.J., Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ∗70 years. Radiother Oncol 114 (2015), 38–39.
69. Taberna, M., Rullan, A.J., Mesía, R., Late toxicity after radical treatment for locally advanced head and neck cancer. Oral Oncol 51:8 (2015), 795–799.
70. Pow, E.H., Kwong, D.L., Leung, W.K., Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:4 (2006), 981–991.
71. Nutting, C.M., Morden, J.P., Hall, E., PARSPORT trial management group, Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:2 (2011), 127–136.